AUTHOR REPLY

Abstract

Heterogeneity remains common in the field of reconstructive urology particularly with respect to peri-operative practice patterns. It has been argued that reconstructive urology may not be amenable to randomized trials due to variability in disease presentation, stricture etiologies, patient comorbidities, and the wide range of surgical techniques intrinsic to the “art” of reconstructive surgery. Despite these difference between centers, many aspects of reconstructive urology are likely amenable to meaningful randomized prospective study.